AI Engines For more Details: Perplexity Kagi Labs You
Uric Acid Reduction: Benzbromarone works by decreasing the production of uric acid in the body and increasing its excretion through the urine. By lowering uric acid levels, it helps prevent the formation of uric acid crystals in the joints, reducing the frequency and severity of gout attacks.
Gout Treatment: Benzbromarone is used as a long-term treatment for gout to prevent recurrent attacks and reduce the risk of complications such as joint damage and kidney stones. It is typically prescribed for patients who do not respond adequately to other medications like allopurinol or who experience intolerable side effects from those drugs.
Hyperuricemia: Benzbromarone is also used to treat hyperuricemia (elevated uric acid levels) in patients with conditions such as gout or certain types of kidney stones. By lowering uric acid levels, it helps reduce the risk of developing gout attacks and related complications.
Kidney Stone Prevention: By promoting the excretion of uric acid through the urine, benzbromarone can help prevent the formation of uric acid kidney stones, a common complication of gout and hyperuricemia.
Anti-inflammatory Effects: In addition to its uric acid-lowering properties, benzbromarone may have mild anti-inflammatory effects that help reduce pain, swelling, and inflammation associated with acute gout attacks.
Renal Function Improvement: Some studies suggest that benzbromarone may have beneficial effects on kidney function, particularly in patients with gout-related kidney damage or impaired renal function. It may help improve renal function by reducing uric acid deposition in the kidneys and preventing further kidney damage.
Cardiovascular Health: There is evidence to suggest that lowering uric acid levels with benzbromarone may have cardiovascular benefits, including a reduced risk of cardiovascular events such as heart attacks and strokes. However, more research is needed to confirm these effects.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
Acne | 0.5 | -0.5 | |
ADHD | 6.7 | 1 | 5.7 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.5 | 1 |
Allergic Rhinitis (Hay Fever) | 2.8 | 2.4 | 0.17 |
Allergies | 6.9 | 3.5 | 0.97 |
Allergy to milk products | 2 | 1.2 | 0.67 |
Alopecia (Hair Loss) | 2.5 | 2.5 | |
Alzheimer's disease | 5.4 | 7.2 | -0.33 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.3 | 1.1 | 2 |
Ankylosing spondylitis | 5.2 | 2.5 | 1.08 |
Anorexia Nervosa | 0.5 | 3 | -5 |
Antiphospholipid syndrome (APS) | 3 | 0.2 | 14 |
Asthma | 2 | 1 | 1 |
Atherosclerosis | 2 | 3 | -0.5 |
Atrial fibrillation | 4.5 | 3 | 0.5 |
Autism | 14 | 11.4 | 0.23 |
Barrett esophagus cancer | 0.5 | 0.5 | 0 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 2 | 2 | 0 |
Brain Trauma | 1 | 1 | 0 |
Carcinoma | 5.4 | 4 | 0.35 |
Celiac Disease | 3 | 4.7 | -0.57 |
Cerebral Palsy | 1.5 | 2 | -0.33 |
Chronic Fatigue Syndrome | 7.9 | 9.4 | -0.19 |
Chronic Kidney Disease | 3.6 | 2.5 | 0.44 |
Chronic Lyme | 1 | -1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 3 | 1 | 2 |
Chronic Urticaria (Hives) | 1.8 | 2 | -0.11 |
Coagulation / Micro clot triggering bacteria | 1.8 | 2 | -0.11 |
Colorectal Cancer | 7.2 | 1.5 | 3.8 |
Constipation | 1.7 | 1 | 0.7 |
Coronary artery disease | 2.5 | 1 | 1.5 |
COVID-19 | 16 | 19.8 | -0.24 |
Crohn's Disease | 10.7 | 7.5 | 0.43 |
cystic fibrosis | 0.8 | 1.5 | -0.88 |
deep vein thrombosis | 0.8 | 1.5 | -0.88 |
Depression | 14.5 | 11.7 | 0.24 |
Dermatomyositis | 0.5 | 0.5 | 0 |
Eczema | 1.3 | 3.5 | -1.69 |
Endometriosis | 4.2 | 1 | 3.2 |
Eosinophilic Esophagitis | 0.5 | 0.5 | |
Epilepsy | 4.2 | 3 | 0.4 |
Fibromyalgia | 4.5 | 3.8 | 0.18 |
Functional constipation / chronic idiopathic constipation | 8.2 | 6.3 | 0.3 |
gallstone disease (gsd) | 2.8 | 1.5 | 0.87 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.5 | 1.5 | 0.67 |
Generalized anxiety disorder | 2.8 | 2.9 | -0.04 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 2 | 2 | 0 |
Halitosis | 1 | 0.5 | 1 |
Hashimoto's thyroiditis | 3.3 | 1.2 | 1.75 |
Hidradenitis Suppurativa | 1.2 | 1.2 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 4.4 | 1.5 | 1.93 |
hypercholesterolemia (High Cholesterol) | 1 | 0 | 0 |
hyperglycemia | 0.3 | 2 | -5.67 |
Hyperlipidemia (High Blood Fats) | 1 | 0.5 | 1 |
hypersomnia | 0.7 | -0.7 | |
hypertension (High Blood Pressure | 3.3 | 6.2 | -0.88 |
Hypothyroidism | 2 | -2 | |
Hypoxia | 1 | 1 | |
IgA nephropathy (IgAN) | 5.3 | -5.3 | |
Inflammatory Bowel Disease | 7.2 | 11.9 | -0.65 |
Insomnia | 1.5 | 1 | 0.5 |
Intelligence | 1.3 | 1 | 0.3 |
Intracranial aneurysms | 2 | 0.5 | 3 |
Irritable Bowel Syndrome | 5.3 | 4.3 | 0.23 |
Liver Cirrhosis | 6.5 | 4.2 | 0.55 |
Long COVID | 12.2 | 12.1 | 0.01 |
Low bone mineral density | 1 | -1 | |
Lung Cancer | 1.2 | 1.5 | -0.25 |
ME/CFS with IBS | 2 | 4 | -1 |
ME/CFS without IBS | 3.6 | 3.4 | 0.06 |
Menopause | 2.9 | 2.9 | |
Metabolic Syndrome | 11.9 | 10.8 | 0.1 |
Mood Disorders | 17.3 | 12.2 | 0.42 |
multiple chemical sensitivity [MCS] | 1.5 | 0.5 | 2 |
Multiple Sclerosis | 8.1 | 8 | 0.01 |
Multiple system atrophy (MSA) | 1.1 | 1.5 | -0.36 |
Neuropathy (all types) | 1 | 0.3 | 2.33 |
neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.7 | 6.9 | -0.86 |
NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
Obesity | 11.7 | 7 | 0.67 |
obsessive-compulsive disorder | 8.6 | 6.3 | 0.37 |
Osteoarthritis | 3.8 | 0.5 | 6.6 |
Osteoporosis | 2.2 | 1 | 1.2 |
pancreatic cancer | 1 | 1 | |
Parkinson's Disease | 3.8 | 5.7 | -0.5 |
Polycystic ovary syndrome | 3.7 | 3 | 0.23 |
Postural orthostatic tachycardia syndrome | 0.5 | 1 | -1 |
Premenstrual dysphoric disorder | 1.5 | 0.5 | 2 |
primary biliary cholangitis | 0.5 | 0.8 | -0.6 |
Psoriasis | 6 | 4 | 0.5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.9 | 5.4 | 0.83 |
Rosacea | 1.8 | 1 | 0.8 |
Schizophrenia | 8 | 3 | 1.67 |
scoliosis | 0.5 | 0.7 | -0.4 |
Sjögren syndrome | 3.3 | 4.3 | -0.3 |
Sleep Apnea | 2.5 | 2.5 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.9 | 0.67 |
Stress / posttraumatic stress disorder | 4 | 3.5 | 0.14 |
Systemic Lupus Erythematosus | 6.5 | 2.5 | 1.6 |
Tic Disorder | 2 | 2.6 | -0.3 |
Tourette syndrome | 0 | 0.5 | 0 |
Type 1 Diabetes | 5.5 | 3.5 | 0.57 |
Type 2 Diabetes | 12.4 | 9.6 | 0.29 |
Ulcerative colitis | 4.2 | 7.1 | -0.69 |
Unhealthy Ageing | 9.5 | 3 | 2.17 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.